Skip to Content
  • Age
    38, 38
  • Title
    Cofounder and CEO; Cofounder and president
  • Company
    Guardant Health

Guardant’s founders Eltoukhy and Talasaz want to remake cancer screening with their “liquid biopsy” technology, which can sniff out DNA fragments in the blood that indicate cancer-related biological markers. The method has drawn plenty of interest — and capital — despite initial skepticism. Guardant raised $360 million in May, and aims to sequence more than 1 million cancer patients’ DNA within five years.

Fortune Data StoreLooking for leads, investment insights, or competitive intelligence?Get Premium Access

40 Under 40

List Debut
NEW